Cure My Disease

Don't miss your cure!

 Log in / Sign up

CAR-T therapy takes on lupus and scleroderma in early trial

NCT ID NCT06708845

Recruiting now Disease control Sponsor: Miltenyi Biomedicine GmbH Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new treatment called zamto-cel, a CAR-T cell therapy, for people with severe lupus or scleroderma that hasn't improved with standard treatments. The study will enroll 48 participants and primarily look at safety and side effects. Participants first receive chemotherapy to prepare their bodies, then the modified immune cells are given as a one-time infusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zamtocabtagene autoleucel (zamto-cel), a CAR-T cell therapy, given after chemotherapy
What this could lead to
If it works, this could point toward a new treatment option for people with severe autoimmune diseases that haven't responded to standard therapies.
What could go wrong
This is a very early (Phase 1) and small (48 people) trial focused on safety, not yet on effectiveness. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease diffuse cutaneous systemic sclerosis diffuse scleroderma immune system disorder lupus nephritis systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS LUPUS NEPHRITIS SYSTEMIC LUPUS ERYTHEMATOSUS SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Froedtert Hospital and the Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.